Related Experiment Videos
Should supportive care be started before initiating cancer treatment?
Utae Katsushima1, Eisuke Ochi2, Yuta Yamanaka3
1Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan. katsushima.uta@kmu.ac.jp.
Purpose:
This comment proposes that the diagnostic waiting period (DWP), defined as the interval from the first specialist visit to anticancer treatment initiation, should be recognized as an opportunity for early supportive care in patients with advanced lung cancer.
Methods:
We discuss the clinical rationale for initiating low-burden supportive care at the first specialist visit, drawing on prior observations of clinical deterioration before treatment initiation and feasibility data from a home-based exercise program during the DWP.
Results:
The DWP is often necessary for imaging, tissue sampling, staging, molecular testing, and treatment planning, but patients may experience anxiety, inactivity, anorexia, weight loss, and functional decline during this period. A first-visit supportive care model could include patient education, safe physical activity guidance, nutritional screening, symptom assessment, and timely referral to rehabilitation, dietetic, nursing, or palliative care services.
Conclusion:
Reframing the DWP from passive waiting to active preparation may help preserve physical reserve, confidence, and treatment readiness before systemic therapy. Future studies should evaluate which patients should be prioritized, which interventions are most useful, and which outcomes best capture the value of this early supportive care approach.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...